This study is a prospective, parallel, placebo-controlled, double-blind multicenter trial with random allocation to one of two treatment limbs; 5- day iloprost or 5-day placebo. The endpoints for efficacy will be: (1) reduction in total duration of Raynaud's attacks, and/or Raynaud's condition scores, (2) reduction in number of cutaneous ischemic finger lesions (ulcers, fissures, and paronychia), (3) improvement in quality of life, and (4) increased tolerance to cold.
Showing the most recent 10 out of 336 publications